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1.  IntroductIon
Anthrax is caused by Bacillus anthracis, a Gram positive, 
spore forming, non-motile bacterium. Its spores are extremely 
resistant to natural conditions and can survive for several 
decades in the environment1. Besides a well known bio-threat 
disease, cutaneous anthrax is a public health disease also in 
several countries where agriculture is the major source of 
income2. Anthrax is a zoonotic disease, therefore, it is spread 
either from infected animals to human through contact or using 
contaminated animal products3. Worldwide, approximately 
20,000 to 1,00,000 human cases of anthrax occur annually4. 
Mainly, two major factors, i.e. a tripartite toxin and the poly-
D-glutamic acid capsule are responsible for the virulence 
of B. anthracis5. Human anthrax has three major clinical 
forms on the basis of route of infection viz. cutaneous (skin), 
gastrointestinal (ingestion) and pulmonary (through inhalation 
of spores)1,6. The cutaneous route accounts for 95 per cent 
and inhalational route for 5 per cent anthrax cases reported, 
while gastrointestinal anthrax is quite rare, mainly due to 
underreporting of the disease7. If not treated well in time, all 
three forms of anthrax can be fatal. Therefore, early treatment 
of cutaneous anthrax is usually curative, and early treatment of 
all forms is important for recovery. Because B. anthracis has 
a high probability for use as an agent in biological terrorism, a 
lot of research is being carried out on its detection, protection 
and decontamination1,8-10. 
The anthrax toxin is secreted as three distinct proteins, 
which are named as protective antigen (PA), lethal factor (LF) 
and edema factor (EF) and their activities have been well 
described previously11,12. PA is non-toxic and combines with 
EF and LF to form edema toxin and lethal toxin, respectively. 
Therefore, being a central component of both the anthrax toxin 
complexes, PA has been a good target for development of 
vaccines.
PA is an 83 kD protein which has 4 different domains and 
each domain has its unique role in toxin function. Domains can 
exist independently from full protein because these are single-
protein subunits and can retain the structural and functional 
integrity13. Domain 1 is made up of amino acid (aa) residues 1 
to 258 and contains the furin recognition site RKKR, which is 
cleaved to release the N- terminal PA20 (aa 1-167) fragement14. 
The remaining portion of domain 1 has interaction site for LF 
and EF, and two Ca++ binding sites15-17. Domain 2 (aa 259 to 
487) helps in binding of PA63 monomers. Besides, a loop 
from domain 2 has contact with the host cell receptor binding 
site18. Besides, Domain 2 forms the heptamer of PA63 along 
with Domain 3 (aa 488 to 595), and in this process, domain 2 
becomes buried and inaccessible, along with domain 1, while 
domain 3 remains accessible with domain 417. This heptameric 
pore of PA on the cell surface allows LF or EF binding, and 
subsequently receptor mediated endocytosis of toxin complexes 
into the cell19,20. Domains 4 (aa 596 to 735) is responsible for 
binding of heptamer to the host cell via cellular receptors18,21. 
As the domains play different roles in toxin function, therefore, 
there can be different mechanisms of protection because of 
differences in their immunogenic profiles.
In this study, we have cloned, expressed and purified the 
various domains of PA. The recombinant proteins were used 
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to develop enzyme-linked immunosorbent assay (ELISA) to 
determine the sero-reactivity of these domain proteins along 
with full PA with human cutaneous anthrax serum samples. 
2.  MetHods And MAterIAls
2.1 cloning, expression and Purification of 
recombinant PA domains 
The genes for various domains of PA i.e. Domain 1 
(PAD1), Domain 2 (PAD2) and Domain 4 (PAD4) were 
amplified by PCR using the primer given in Table 1. Genomic 
DNA of B. anthracis Sterne was used as DNA template. The 
PCR products were purified from the agarose gel. The purified 
PCR products and pET32a+ vector were digested with BamH1 
and Xho1 independently. The restricted PCR products and 
vector were ligated using T4 DNA ligase at 16°C overnight. 
The ligated plasmid was transformed in the competent cells 
of Escherichia coli BL21 (DE3). The positive transformants 
were selected on LB agar plates containing ampicillin (100 
µg/ml). Further, the transformation was confirmed by the 
colony PCR using the primers for individual domains. The 
bacterial cells were grown in Luria-Bertani (LB) broth to an 
optical density (OD600) of 0.5-0.6 and then induced with 1mM 
isopropyl-β-D-thiogalactoside at 37 °C for 4 h for expression 
of recombinant proteins. The cultures pellet was subjected to 
solubility analysis of the expressed proteins. Recombinant 
proteins were purified by Ni-NTA columns (Qiagen) as per the 
standard protocol. The proteins were separated by 12 per cent 
SDS-PAGE followed by Coomassie blue staining to check the 
purity. The same set of proteins was transferred from gel to 
nitrocellulose membrane and probed with anti-his monoclonal 
antibodies. The concentration of purified proteins was estimated 
by BCA method after dialysis and passing through Amicon 
ultra centrifugal filter device (Millipore).
 
2.2 serum samples
A total of 43 serum samples from clinically proved 
cutaneous anthrax patients from the anthrax endemic area were 
selected in this study22,23. The patients were clinically and 
epidemiologically well-defined. The serum samples were 
confirmed for the presence of anti-PA IgG in the previous studies23. 
2.3 elIsA
Maxisorp flat-bottom 96-well microtiter plates (Nalge 
Nunc International, Denmark) were coated with 100 µl per 
well of phosphate-buffered saline (PBS), pH 7.4 containing 2 
µg/ml of recombinant PA domains as well as full PA protein 
(PA83) and incubated overnight at 4°C. The recombinant full 
PA (PA83) was obtained from Alpha Diagnostics International 
Company, USA. The antigen-coated plates were washed three 
times with wash buffer (PBS containing 0.1 per cent Tween 20) 
using ELx 508MS microplate washer (Biotek Instruments Inc, 
USA). A 300 µl of 3  per cent skim milk in PBS was added in 
each well as blocking buffer and the plate was incubated for 1 
h at 37 °C. The human cutaneous anthrax serum samples were 
diluted to 1:1000 in PBS containing 1 per cent skim milk, pH 
7.4 and 100 µl of each diluted serum was added to each well 
of ELISA plate. After incubation for 1 h at 37 °C, the plate was 
washed three times with wash buffer and blotted dry on a paper 
towel. To detect the bound antibody, 100 µL per well of HRP-
conjugated goat anti-human IgG (Sigma- Aldrich) diluted to 
1:3000 in PBS containing 1 per cent skimmed milk was added. 
After incubation for 1 h at 37 °C, the plate was washed again 
three times with wash buffer and added 100 µL per well of 
TMB (3,3’, 5,5’-tetramethylbenzidine) as substrate (Sigma 
Aldrich, USA). The colour development was read after 15 min 
of incubation at room temperature at 630 nm using an ELISA 
plate reader (BioTek Instruments Inc, USA). The OD values 
were expressed in ELISA units (EU). All the serum samples 
were tested in duplicate.
3.  stAtIstIcAl AnAlysIs
Significance of the differences in mean IgG titers using 
different PA domains as antigens. was tested using a one way 
analysis of variance (ANOVA). Tukey’s multiple comparison 
tests were applied to analyse pair wise comparison between 
different groups by using GraphPad version 6.00 for Windows, 
GraphPad Software, La Jolla California USA (www.graphpad.
com) as described previously22.
4.  results And dIscussIon
4.1 cloning, expression and Purification of domain 
Proteins
All the genes for different recombinant domains i.e. 
PAD1, PAD2 and PAD4 were successfully amplified by PCR 
and digested with BamH1 and Xho1 restriction enzymes. The 
restricted products were ligated into pre-digested pET32a+ 
vector and transformed into E. coli BL21 (DE3). Transformation 
of each gene was confirmed by colony PCR (Fig. 1). The 
recombinant PAD1, PAD2 and PAD4 domain proteins of 46 
kDa, 43 kDa and 33 kDa were expressed in BL21 (DE3) at 
37 °C. The expression of the desired recombinant 
protein was tested by inducing the clones with IPTG.
The expression profile of recombinant proteins PAD1, 
PAD2 and PAD4 was analysed by SDS-PAGE for 
un-induced and IPTG-induced cultures. The 6X-His 
tag was present at N-terminus for the purification of 
proteins. Cells lysis under native conditions revealed 
the association of recombinant PAD1 and PAD4 with 
the supernatant fraction, demonstrating that the PAD1 
and PAD4 proteins were soluble. However, PAD2 
was associated with pellet fractions, demonstrating 
that PAD2 was insoluble. Therefore, the purification 
of PAD1 and PAD4 proteins was carried out in native 
domain 
primer
oligo sequence Amplicon 
size (bp)
PAD1
CGAGGATCCGCAGAAGTTAAACAGGAGAACCG
779
GATCTCGAGTAAGCTGCCACAAGGGGGTG
PAD2
CGAGGATCCCACCCCCTTGTGGCAGCTTAT
691
GATCTCGAGGCGGTAACACTTCACTCCAG
PAD4
CGAGGATCCTATGATAGAAATAACATAGCAG
414
GATCTCGAGTCCTATCTCATAGCCTT
Solid under line indicates the sequence of Bam H1, whereas dotted underline indicates the 
sequence of Xho1 restriction enzymes
table 1. list of oligos used in the study
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conditions, whereas PAD2 protein was solubilised in 8 M 
urea and purified by Ni-NTA affinity chromatography. 
The recombinant proteins were tested on SDS-PAGE for 
purity as shown in Fig. 2(a). The yield of PAD1, PAD2 
and PAD4 was 9 mg/L, 16 mg/L, and 18 mg/L under 
shake flask culture conditions, respectively. The proteins 
corresponding to their molecular weights  were recognised 
by anti-histidine antibody in a western blot experiment 
(Fig. 2(b)). 
4.2 determination of reactivity of serum with 
Various PA Antigens
The mean EU values of IgG against various PA antigens 
have been given in Table 2. The mean EU (overall 95 per 
cent confidence interval) in tested sera with PA83, PAD1, 
PAD2 and PAD4 varied between 0.79 to 1.08, 0.46 to 0.59, 
0.73 to 0.91 and 0.49 to 0.66 EU, respectively. The mean EU 
values of PA83 were highest followed by PAD2, PAD4 and 
PAD1 (Fig. 3). Tukey’s multiple comparison tests revealed that 
there were significant differences between the mean EU values 
of PA83 with PAD1 and PAD4 (Table 3). However, EU values 
of PA83 and PAD2 were not significantly different. The mean 
EU values of PAD2 were also significantly different from the 
mean EU values of PAD1 and PAD4, whereas the difference 
in mean EU values of PAD1 and PAD4 was not significant.. 
The frequency distribution of anti-PA IgG EU for PA83 and 
different domains is given in Fig. 4. 
PA is the major target for development of the diagnostic 
assays as well as for vaccines and post exposure therapy. It has 
been established in animal models  that the immune response to 
PA is central to protection against B. anthracis24. In cutaneous 
anthrax cases, the immune response against PA is detectable 
Figure 3. IgG responses to anthrax PA domain protein in 
cutaneous anthrax serum samples (diluted 1:1000) 
obtained from human.
Figure 1. PCR for confirmation of transformation. Lane 1: 
standard protein marker, lane 2: PAd1, lane 3: 
PAd2, and lane 4: PAd4.
PA83       PAd1 PAd2 PAd4
Total number of values 43 43 43 43
Number of excluded values 0 0 0 0
Number of binned values 43 43 43 43
Minimum 0.44 0.176 0.272 0.197
25% Percentile 0.5845 0.329 0.583 0.3615
Median 0.825 0.509 0.822 0.4995
75% Percentile 1.107 0.6665 1.004 0.7135
Maximum 2.274 1.042 1.661 1.2925
Mean 0.942227 0.531593 0.820849 0.57943
Std. Deviation 0.463014 0.215787 0.29089 0.278358
Std. Error of Mean 0.070609 0.0329072 0.0443603 0.0424492
Lower 95% CI of mean 0.799732 0.465184 0.731326 0.493764
Upper 95% CI of mean 1.08472 0.598002 0.910371 0.665096
table 2. comparison of anti-PA IgG titer expressed as elIsA 
units (eu) for various domains.
Figure 2. (a) SDS-PAGE Profile of Ni-NTA purified recombinant 
domain proteins and (b) Western blot with anti-His 
antibodies. lane 1: standard protein marker, lane 
2: PAd1, lane 3: PAd2 and lane 4: PAd4. 
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after 10 to 11 days of onset of symptoms and remains detectable 
after 8 month to 16 month of exposure25. PA has four domains 
and each domain plays a critical role in toxin action. Therefore, 
in this study, antibody responses for individual domain antigen, 
with human anthrax infected sera were evaluated separately by 
enzyme linked immunosorbent assays (ELISAs). Each domain 
has specific role in the intoxication process of anthrax toxin26. 
The study revealed that there is great variation in the immune 
response of individual domain. Among the domains, the highest 
immune response was found against domain 2 (PAD2), which 
is necessary for membrane insertion and heptamerisation of 
PA. Next higher response was found against domain 4 (PAD4), 
which has overall more exposure during heptamerisation 
, and more specifically, the accessibility of an exposed loop 
region (703–722)27. Besides, it binds to the host receptor 
also. However, A83 exhibited the highest immune response 
showing that all four domains are required for the maximum 
protection. Previously, the immunogenicity of different 
domains has been found variable in within and between 
genetically different strains of mice28. However, in mouse 
model, domain 1 elicited the highest immune response, 
whereas domain 2 or 4 were significantly less effective 
in eliciting the higher antibody titre28. Because the host 
genetics plays a very important role in antibody response, 
therefore domains could elicit different immune response 
in mouse and human. 
The immunoreactivity of human cutaneous anthrax 
serum samples with individual PA domains showed that 
besides full PA protein (PA83), individual domain 2 and 4 
can also be good target for  development of vaccine by gener-
ating the chimeric protein with other relevant proteins. 
Besides, these domains can be used for development of sero-
diagnostic assays. 
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